189347-40-8

Usage

Uses

Used in Pharmaceutical Synthesis:
4,4-DIFLUORO-1-(4-METHOXY-PHENYL)-BUTANE-1,3-DIONE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new molecules with potential medicinal properties.
Used in Organic Chemical Synthesis:
In the field of organic chemistry, 4,4-DIFLUORO-1-(4-METHOXY-PHENYL)-BUTANE-1,3-DIONE serves as a valuable component in the creation of various organic chemicals, highlighting its versatility and importance in chemical research and development.
Given the potential applications and reactivity of 4,4-DIFLUORO-1-(4-METHOXY-PHENYL)-BUTANE-1,3-DIONE, it is crucial to handle this chemical with care and adhere to proper safety protocols during its use in laboratories and industrial settings.

Upstream product

• 454-31-9 ethyl difluoroacetate 
• 100-06-1 1-(4-methoxyphenyl)ethanone 

Downstream Products

• 1418197-36-0 (5-(difluoromethyl)-3-(4-methoxyphenyl)isoxazol-4-yl)(4-methoxyphenyl)methanol 
• 1418197-35-9 2,2-difluoro-1-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)isoxazol-5-yl]ethanol 
• 1418197-34-8 (5-(difluoromethyl)-3-(4-methoxyphenyl)isoxazol-4-yl)(phenyl)methanol 
• 1418197-33-7 2,2-difluoro-2-[3-(4-methoxyphenyl)isoxazol-5-yl]-1-phenylethanol 
• 1260813-24-8 5-(difluoromethyl)-3-(4-methoxyphenyl)isoxazole 
• 929606-79-1 C₁₇H₁₃BrF₂N₂O 
• 929606-94-0 C₁₇H₁₃BrF₂N₂O 
• 151507-09-4 3-(Difluoromethyl)-5-(4-methoxyphenyl)-1-[4(methylthio)phenyl]pyrazole 

Relevant academic research and scientific papers

PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES

The present invention relates to novel pyrazolo- and imidazo-pyrimidine derivatives of formula (I) wherein A, D, E, L, M, Q, R1, R2 and R3 are as defined in the description and claims and to processes for their preparation, pharmaceutical compositions containing said derivatives and their use in the prevention and treatment of diseases.

Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine

Structure-activity relationship (SAR) studies of 2-[3-di(and tri)fluoromethyl-5-arylpyrazol-1-yl]-5-methanesulfonylpyridine derivatives for canine COX enzymes are described. This led to the identification of 12a as a lead candidate for further progression. The in vitro and in vivo activity of 12a for the canine COX-2 enzyme as well as its in vivo efficacy and pharmacokinetic properties in dog are highlighted.

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)- 3(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide (sc-58635, celecoxib)

A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC- 236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of 1i (4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.